Mesoblast Provides Update on Clinical Programs of Prochymal for Crohn's Disease and Acute Graft Versus Host Disease
28 avr. 2014 21h51 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, April 28, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided an update on its clinical programs using the...
Key Pharmaceutical Executive Joins Mesoblast
10 mars 2014 19h48 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 10, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Jonathan R. Symonds, CBE, the former...
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
05 mars 2014 19h24 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, March 5, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief...
Mesoblast Reports Strong Half-Year Financial Results
25 févr. 2014 17h00 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
19 févr. 2014 21h02 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the...
Boardroom Radio Interview with Mesoblast Chief Executive
02 févr. 2014 20h06 HE
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
29 janv. 2014 18h31 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the...
Mesoblast Reports Positive Type 2 Diabetes Trial Results
03 déc. 2013 19h10 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced top-line results from the Phase 2 trial of...
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
24 nov. 2013 19h16 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a...
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
22 nov. 2013 06h00 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal...